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Measuring and monitoring performance—be it waiting
list and posttransplant outcomes by a transplant cen-
ter, or organ donation success by an organ procure-
ment organization and its partnering hospitals—is an
important component of ensuring good care for peo-
ple with end-stage organ failure. Many parties have an
interest in examining these outcomes, from patients
and their families to payers such as insurance com-
panies or the Centers for Medicare and Medicaid Ser-
vices; from primary caregivers providing patient coun-
seling to government agencies charged with protect-
ing patients.
The Scientific Registry of Transplant Recipients pro-
duces regular, public reports on the performance of
transplant centers and organ procurement organiza-
tions. This article explains the statistical tools used
to prepare these reports, with a focus on graft sur-
vival and patient survival rates of transplant centers—
especially the methods used to fairly and usefully com-
pare outcomes of centers that serve different popula-
tions. The article concludes with a practical application
of these statistics—their use in screening transplant
center performance to identify centers that may need
remedial action by the OPTN/UNOS Membership and
Professional Standards Committee.
Key words: Methodology, OPTN, patient survival, pro-
fessional standards, risk adjustment, SRTR, transplant
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Introduction
Many audiences, many reports
Reporting the results of transplant centers and organ pro-
curement organizations (OPOs) is one of the many contract
responsibilities of the Scientific Registry of Transplant Re-
cipients (SRTR). These analyses have a wide range of in-
tended audiences within the transplant community, each
with different understandings of clinical and statistical con-
cepts, and each with different goals:
(i) Patients and families may use them to find a transplant
program with good experience among similar patients.
(ii) Transplant professionals, such as surgeons or admin-
istrators, may use them to help explain a patient’s
prospects for recovery, or as a quality control mech-
anism for benchmarking against other programs.
(iii) Insurance companies and other payers may use them
to ensure good care for the patients they serve.
(iv) Regulatory bodies both within and outside of the Organ
Procurement and Transplantation Network (OPTN) may
use them to help identify programs in need of remedial
action or further study.
The publicly available transplant center-specific reports
(CSRs) published on the SRTR website at www.
ustransplant.org are the most widely used of a whole ‘fam-
ily’ of tools for program-specific reporting produced by the
SRTR at least every 6 months. Similar reports document
the organ procurement activity within each donation ser-
vice area (DSA). A quarterly report for the OPTN Member-
ship and Professional Standards Committee (MPSC) helps
that committee identify centers for performance review. A
prescribed set of statistics is prepared as part of a ‘Stan-
dardized Request for Information’ and made available for
centers to submit to insurers requesting information about
center performance. All of these tools employ the same
methodology for measuring outcomes; these are the meth-
ods discussed in this article.
The scope of questions addressed in these reports covers
the entire spectrum of the transplant process. The organ
procurement organization-specific reports (OSRs) examine
the process of identifying and recovering donors. The CSRs
begin by examining pretransplant activity and outcomes on
the waiting list. These often-overlooked statistics, such as
the mortality and transplant rates contained in Table 3 of
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the CSRs, are an important component of the transplant
process, as posttransplant outcomes are irrelevant to a pa-
tient who might die while still awaiting an organ. However,
by far the most attention is focused on the graft and pa-
tient survival reported in Tables 10 and 11 of the CSRs.
Therefore, we focus most of our explanation here on the
techniques used for measuring these posttransplant out-
comes, many of which are also applicable to other sections
of the reports.
We conclude the article with a look at how one monitor-
ing body, the OPTN MPSC, implements these statistics to
help recommend changes for improving transplant center
operations.
Advantages of a Standardized Calculation
Using SRTR-calculated center-specific statistics provides
several advantages over having each center report its own
statistics:
(i) Uniform statistical methodology: The methods used
by the SRTR are standard and accepted within the sta-
tistical and medical communities.
(ii) Uniform and required data collection: Accurate sub-
mission of transplant data is required for participation
in the OPTN organ allocation system. The United Net-
work for Organ Sharing (UNOS), the contractor for the
OPTN, works with help from the SRTR to ensure the
accuracy and reliability of these data.
(iii) No duplication of effort by facilities: Calculating
these statistics can be a tedious task that is most
efficiently programmed for all centers at the same
time.
(iv) Extra ascertainment of mortality: The SRTR helps
find information about patients who become lost to
follow-up. Outcomes for these patients may be very
difficult or even impossible for transplanting centers to
track and report. Extra ascertainment builds trust in the
completeness of reporting.
(v) Risk-adjusted comparison points: Comparison of
outcomes should be based on risk-adjusted models
that account for the types of patients treated. Without
national data, it is impossible for centers to calculate
risk-adjusted comparison points.
Interpreting Posttransplant Outcomes
Posttransplant outcome tables dominate the questions and
concerns about the CSRs, and have figured prominently
in the Conditions of Participation for funding transplant
hospitals recently proposed by the Centers for Medicare
and Medicaid Services (CMS) (1). The issues illustrated by
these tables apply to many of the other statistics in the re-
ports, such as risk-adjusted comparison of transplant and
mortality rates from the waiting list, or risk-adjusted com-
parisons of donation rates for OPOs. We focus here on
posttransplant outcomes as the primary examples in our
examination of CSRs, though waiting list outcomes are also
raised as secondary examples.
Percentage surviving at the end of period: an
interpretable result
Table 1 shows portions of CSR Table 11, Patient Survival
after Transplant, published in the July 2005 release of the
CSRs. We will call the example liver program shown here
“Hospital A.” Table 1 presents much information that is re-
ferred to throughout this article, but it is limited to results
for 1 year following transplantation. Similar columns, pro-
duced for outcomes at 1 month and 3 years, are omitted.
The first panel of results, beginning at line 2, shows the
percentage of patients surviving at the end of the period
(in this case, 1 year). The percentage of patients surviving is
intuitively understandable, and meaningful to a wide range
of audiences—the reader, perhaps a patient, learns that
in recent history, 87.78% of other patients who received
a liver transplant at Hospital A were alive a full year after
transplantation (line 3). Other measures, such as a rate per
year at risk, may not be as intuitively understandable to
most audiences.
The same patient, or perhaps a transplant administrator,
may compare that survival percentage to the national aver-
age of 86.26%, also on line 2. While a conclusion that the
center has above-average results compared to the national
average is accurate at face value, we must look further to
determine whether this is either:
(i) because the center is ‘above average’ in its treatment
practices, or
(ii) because the types of patients treated by this center
tend to have better outcomes no matter where they
are treated (e.g. they are younger or start off with fewer
complications than patients in other centers).
This distinction is addressed by the concept of ‘expected
survival.’
Expected survival
The notion of expected survival addresses the critical ques-
tion, ‘What rate would be expected for the patients at this
center if they had outcomes comparable to the typical na-
tional experience for similar patients?’
Line 4 of Table 1 (‘Expected, based on national experi-
ence’) allows the reader to examine whether a center’s
performance is itself above average, or whether the cen-
ter starts off with healthier patients. In Hospital A, from
Table 1, 89.41% of ‘similar’ patients, nationwide, were alive
1 year after transplant. Two conclusions can be made:
(i) Because expected survival is higher for this center than
the national average, the case-mix of patients treated by
this center may be easier to treat than average patients
throughout the country.
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Table 1: Center-specific report Table 11—patient survival after transplantation, sample liver center
‘Hospital A’
Center National
1 year 1 year
Adult (Age 18+)
1 Transplants (n = number) 90 10 781
2 Percentage (%) of patients surviving at the end of period
3 Observed at this Center 87.78 86.26
4 Expected, based on national experience 89.41
5 Deaths during follow-up period
6 Observed at this center 11 1392
7 Expected, based on national experience 8.48 1392
8 Ratio: observed to expected (O/E) 1.30 1.00
9 (95% Confidence Interval) (0.65–2.32)
10 P-value (2-sided), observed v. expected 0.469
11 How does this center’s survival compare
to what is expected for similar
patients?
Not significantly different
12 Percent retransplanted 5.5 4.4
13 Follow-up days reported by center (%) 91.7 93.9
14 Maximum days of follow-up (n) 365 365
Source: SRTR Center-Specific Reports, www.ustransplant.org, July 2005 Release.
(ii) While the survival rate observed at this center is above
the national average for all liver transplant recipients, it
is in fact below what would be expected for the type
of patients treated by the center.
These conclusions rely on the notion of ‘similar’ patients—
those with characteristics in common that may influence
the waiting list or posttransplant outcome. The character-
istics used to define ‘similarity’ include characteristics that
are associated with survival in the general population, such
as age; and disease-specific factors, such as specific eti-
ology of disease and measures of severity of illness. We
discuss how this list of factors is determined in the section
‘Calculation of Models.’
Table 2 illustrates how adjustment works and why it is
needed. In this table, we assume that the nation consists
of only two kinds of patients: half are ‘older’ (with 80%
1-year survival) and half are ‘younger’ (92% survival), for an
overall national average survival of 86%. At example Hos-
Table 2: Simplified age-based risk adjustment
Age group National At Hospital B Center vs. nation
comparison
Percentage
in group Percent survival No. alive Percent survival
0–44 50% 92% 24 of 25 96% 96 > 92: better
45+ 50% 80% 61 of 75 81% 81 > 80: better
Average Expected Observed
Calculation .5 × 92% + .5 × 80% .25 × 92% + .75 × 80% (24 + 61)/100 85 < 86: worse (wrong);
Result 86% 83% 85% 85 > 83: better (correct)
Source: SRTR.
pital B, 24 of the 25 younger patients survived until 1 year
(96%), as did 61 of the 75 older patients (81%). Within each
age group, the center’s survival rate compares favorably to
the nation’s, even though the center’s 85% overall survival
is lower than the national average. The center’s expected
rate of survival is 83%—80% for the 75 older patients, and
92% for the younger 25 patients. Unlike the comparison
to the national average, the favorable comparison of
the center’s overall survival rate to this expected rate is
consistent with the findings specific to each age group.
Many other important differences besides age exist among
patients and organs. To simultaneously adjust for a long list
of factors in the same way that age is controlled for in this
example, the SRTR uses the Cox regression model (2). This
semi-parametric model is very flexible in the types of data,
event rate patterns and covariates it can incorporate. More
details about the models, including lists of covariates, can
be found in the technical documentation to the CSRs at
www.ustransplant.org/srtr resources.aspx.
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Table 3: Effect of expanded criteria donor definition components
on kidney graft survival
Factor Hazard ratio
Hypertension 1.23
Creatinine > 1.5 1.13
Donor age: 65+ (ref. = 35–49) 1.46
COD Stroke (vs. head trauma) 1.30
‘ECD’ classification 1.21
Calculated as exp (Beta) from 1-year kidney graft survival model,
CSRs released 01/11/2005.
Source: SRTR.
The Cox model allows us to calculate the effect on out-
come for each characteristic of the recipient and donor,
which can be taken together to calculate the expected
outcome for each patient. This effect is how each factor
is ‘weighted’ in the risk-adjustment process. For example,
many programs use expanded criteria donor (ECD) kidneys
for recipients whose expected waiting time for a better kid-
ney increases their risk of dying before receiving a trans-
plant. To ensure that a lower survival rate for transplant
programs using ECD kidneys does not, on its own, indicate
poor performance, we incorporate these donor factors into
the models for expected survival. Table 3 shows many of
the factors used in identifying an ECD kidney and their sep-
arate effects on 1-year graft survival. Not all ECD donors
are characterized by all of these factors. A kidney from a
donor with a history of hypertension, whether classified
as ECD or not, carries with it a risk of graft failure of 1.23
times, or 23% higher, than that of an organ from a donor
without hypertension (Table 3). If that same donor was also
older than 65, the kidney would be another 1.46 times as
likely to fail, for a total elevated risk of 1.23 × 1.46 = 1.80.
By multiplying the hazard ratios listed, note that a kidney
from a donor with all of the characteristics listed in Table 3
represents a graft failure risk more than three times that of
a kidney from a donor with none of these characteristics.
Adjusting for the case-mix of patients is extremely im-
portant in interpreting posttransplant outcomes. Table 4
Table 4: Range of expected 1-year graft survival rates, July 2005 center-specific reports
Range of center expected rates
National 5th 95th
Organ rate Minimum percentile Median percentile Maximum
At all centers
Heart 86.4 61.2 81.9 86.9 90.4 94.7
Lung 80.6 47.3 67.4 80.9 85.2 88.3
Kidney 91.5 84.7 88.2 91.8 94.6 96.8
Liver 82.1 61.0 76.0 82.8 86.8 87.4
At centers with 10 or more transplants in cohort
Heart 79.6 82.8 86.9 90.3 91.2
Lung 52.6 68.1 81.1 84.9 85.8
Kidney 84.7 88.2 91.7 93.9 95.9
Liver 74.8 77.0 82.9 86.6 87.4
Source: SRTR calculations from CSRs released July 2005, www.ustransplant.org.
shows the range of expected 1-year survival for different
organs, suggesting that the mix of patients transplanted
varies tremendously among centers. For example, even
though the national average 1-year liver graft survival was
82.1%, centers’ expected survival ranged from 61.0% to
87.4%. The second panel of the table shows that this wide
variation is not limited to smaller centers that may treat just
a few particularly difficult (or easy) cases. Especially for
centers at the far ends of these ranges of expected sur-
vival, a comparison to the national average survival could
be quite misleading.
Viewpoints on posttransplant outcomes
To return to the analyses shown in Table 1 for Hospital A,
is the difference we see between the observed survival
of 87.78% and the expected rate of 89.41% large enough
to be meaningful? The answer may depend on the user’s
perspective. Table 5 shows three different ways of looking
at the same comparison of outcomes.
The percentage surviving at 1 year is only 2% lower than
expected, an apparently small difference. However, the
same difference appears more consequential when com-
paring the percentage that died, a full 15% higher than
expected. Finally, for the 90 transplants performed over
2.5 years, the count of deaths observed during follow-up
was 30% higher than expected, accounting for 2.5 excess
deaths.
The differences among these interpretations are stark. The
first change from a 2% difference to a 15% difference
reflects the change in denominator—a small percentage
point difference is a much smaller fraction of survival (usu-
ally a large number at 1 year) than of mortality. Several
years after transplant, when survival rates may be close to
50%, this contrast would not be as evident.
The difference between the percentage that died and the
death count is subtler. The expected number of deaths is
calculated according to the time that patients are followed
and surviving after transplant, so the expected number of
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Table 5: Three interpretations comparing the same outcomes, example ‘Hospital A’
Ratio or
Expected Observed relative risk Interpretation
Percentage who survived after 1 year 89.41% 87.78% 0.98 2% lower
Percentage who died after 1 year 10.59% 12.22% 1.15 15% higher
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Figure 1: Calculating expected deaths.
deaths for a patient whose follow-up ends—for any reason,
including death—immediately after transplant is smaller
than it would be if that follow-up extended longer. There-
fore, this last statistic accounts for the difference between
a patient who survives only briefly during follow-up, and
one who survives nearly the entire period, patients who
would be identical in the end-of-period accounting of ‘per-
centage died.’
Figure 1, based on Table 6, illustrates this point. The curve
shows the percentage surviving at each day after trans-
plant for a given type of patient. It falls quickly from 100%,
consistent with the immediate risk of surgery, before lev-
eling out to reach a 1-year survival of 87.2%.
Fifteen days after transplantation, when Patient 1 died, we
would have expected 0.062 deaths. (At any point in time t,
the expected probability of death is calculated as –ln(S(t)),
where S(t) is the survival percentage at that time. For sur-
vival percentages near 100%, this is closely approximated
by 100 minus the survival percentage.) Visually, the ex-
pected probability of death is approximated by the verti-
cal distance down from the horizontal line at 100% to the
survival curve; this distance increases with the time since
transplantation. For Patient 2, who died after 300 days,
the vertical distance is larger and the expected number of
deaths is 0.132. With this example survival curve, we as-
sess a probability of death of 0.137 for any patient surviving
until at least 365 days. Table 6 shows how observed and
expected deaths would be counted and summed if a cen-
Table 6: Aggregating observed and expected events by center,
example “Hospital C”
Observed Expected Ratio of
Days death death observed to
followed events events expected
Patient 1 15 1 0.062 16.10
Patient 2 300 1 0.132 7.56
Patient 3 365 0 0.137 0.00
– – – – –
Patient 15 365 0 0.137 0.00
Sum total 2 1.975 1.01 (Overall ratio)
Note: The ‘sum total’ line reflects the total for all lines, including
the omitted lines for patients 4–14. Each omitted line has 0
observed death events and 0.137 expected death events.
Source: SRTR.
ter, Hospital C, transplanted 15 patients, including these 2
and 13 others who survived 1 year.
For both of the patients who died, the observed number
of deaths (1) is far higher than expected, but more so for
the patient who died on day 15 (1/0.062 = 16-fold higher
than expected) than for the patient who died on day 300
(1/0.124 = 7.5-fold higher than expected). Each of the other
patients has 0 observed and 0.137 expected deaths. For
the 15 patients at Hospital C, the number of observed
deaths (2) and number of expected deaths (1.975) compare
quite closely: the ratio of 1.01 indicates that the center ex-
perienced about 1% more deaths than would be expected
given this patient-risk group.
Note that different types of patients would have different
curves, either higher (better survival) or lower (worse sur-
vival) than the one depicted in Figure 1. For illustration pur-
poses we assume here that all patients are ‘similar’ and
have the same expected survival curve; the actual CSR cal-
culation of expected events takes into account the differ-
ences between patients by using a different survival curve
for each patient.
Returning to Table 1 (CSR Table 11), the second panel (lines
5–10) focuses on these expected (8.48) and observed (11)
deaths after transplant for Hospital A. The ratio’s confi-
dence interval suggests that while we estimate a ratio of
observed to expected deaths of 1.3—or 30% more deaths
than expected—there is a 95% chance that the ‘true’ ratio
of observed to expected lies between 0.65 and 2.32. The
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p-value measures the possibility that any discrepancy be-
tween observed and expected occurred by random chance
alone: in this case, the p-value of 0.469 suggests that there
is about a 47% chance that the difference occurred by ran-
dom chance. Most statistical literature considers a p-value
of less than 0.05 to indicate a ‘statistically significant’ find-
ing; this is the significance threshold used in line 11 of
Table 1.
This panel of CSR Table 11—observed and expected
counts of deaths—is the most appropriate for use by those
who want to identify centers that perform particularly well
or particularly poorly, even though it may not be as intu-
itively interpretable as the percentage surviving 1 year after
transplantation.
Considering pretransplant outcomes
Table 7 shows how the comparison between observed and
expected rates carries over to waiting list outcomes. Hos-
Table 7: Center-specific report Table 3—Transplant and mortality rates among wait-listed patients, sample liver center ‘Hospital D’
This center
U.S.
Waitlist registrations 01/01/2003–12/31/2003 01/01/2004–12/31/2004 01/01/2004–12/31/2004
Sample
Count on waitlist at start 197 236 17 061
Transplant rate
Person Years 167.2 236.8 16 925.7
Living and deceased donors
Removals for transplant 82 86 6144
Transplant rate (per year
on waitlist)
0.49 0.36 0.36
Expected transplant rate 0.31 0.27 0.36




Lower bound 1.26 1.08 NA
Upper bound 1.96 1.67 NA
p-value (2-sided) <0.01 <0.01 NA
How do the rates at this
center compare to
those in the nation?
Statistically higher Statistically higher NA
Deceased donors only (similar content to above)
Mortality rate after being placed on waitlist
Person years 170.0 241.1 17 459.7
Number of deaths 25 25 2424
Death rate (per year on
waitlist)
0.15 0.10 0.14
Expected Death rate 0.12 0.15 0.14




Lower bound 0.81 0.44 NA
Upper bound 1.84 0.99 NA
p-value (2-sided) 0.321 0.045 NA
How do the rates at this
center compare to
those in the nation?
Not significantly different Statistically lower NA
Source: SRTR center-specific reports, www.ustransplant.org.
pital D, shown in this representation of CSR Table 3, has
a rate of 0.36 transplants per year that a patient spends
on the waiting list, exactly the national average for 2004.
The expected transplant rate for this program, only 0.27,
suggests first that the types of patients served by this cen-
ter typically wait longer or are more likely to die before
transplant. The fact that the observed rate is higher than
expected suggests that the program does a good job of
achieving the goal of wait-listing (obtaining a transplant)
for these types of patients—as long as it is not at the ex-
pense of accepting poor-quality organs. This trade-off is
for one reason that it is important to consider both pre-
and posttransplant outcomes.
Other waiting list activity tables (CSR Tables 4 through 6)
show outcomes that may be more interpretable from the
point of view of a patient on the waiting list, helping the
reader understand the likely waiting times and likelihood
of different events at different times after listing.
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Table 8: Methods for addressing loss to follow-up
Kaplan-Meier (KM) Extra ascertainment of mortality
Method Assume lost patients have similar outcomes to
followed patients
Assume a patient is alive unless we know
otherwise from any of many sources (Social
Security, CMS, other transplant centers)
Advantages Helps produce an interpretable ‘percentage
surviving at the end of period’
Verifies center reporting with external sources
Limits bias
Allows patients with incomplete data to contribute
to the results
Available for both graft and patient survival
Disadvantages Subject to biases if lost patients are not similar to
followed ones
Extra sources unavailable for graft survival
Small samples can be unstable
Used in calculating Graft survival (CSR Table 10) Graft survival (CSR Table 10)
Percent surviving at end of period All statistics: mortality is counted as graft failure
at any time while the patient is followedHandles time after last follow-up
Patient survival (CSR Table 11)Patient survival (CSR Table 11)
Percent surviving at end of period All statistics
Handles time after last expected follow-up
Source: SRTR.
Accounting for the Uncertainty of Loss to
Follow-Up
Every transplant program is responsible, as a condition of
its participation in the national organ allocation system, for
reporting on outcomes, such as death and graft failure until
(and sometimes beyond) the time that the transplant is no
longer functioning. However, many patients are difficult to
gather data on following transplantation—particularly kid-
ney recipients, who have an alternative treatment (dialysis)
that does not require them to return to a transplant cen-
ter. Rates at which patients become ‘lost to follow-up’ are
as high as 15% by the third year after kidney transplan-
tation, but less than half as large for other organs (SRTR
analysis).
To calculate estimates of survival for patients who become
lost to follow-up, the SRTR employs both the Kaplan-Meier
(KM) estimation and extra ascertainment of mortality from
additional data sources (Table 8).
The KM method uses the experience of patients who are
followed to estimate the outcomes of patients who are lost
to follow-up (3). For example, if we last know a patient is
alive 6 months after transplantation, the KM method uses
the average outcomes of other patients also alive 6 months
after transplantation to estimate what would likely happen
to this patient. This method allows the calculation of the
intuitively understood ‘percentage surviving at the end of
period’ in Table 1, even when not all patients have been
followed until the end of the period (either because they
have been lost or because the transplant was too recent).
Table 9 shows a simple example of how 1-year survival is
calculated for a cohort of patients of whom half (Group B)
are followed for only 6 months. For the 90 patients in
Group B who are alive at 6 months but not followed there-
after, our best guess is that they will have outcomes simi-
lar to the 86 patients from Group A who also survived until
6 months. For both groups together, the survival rate dur-
ing the first 6 months is 88%, yielding an estimated 1-year
survival rate of 80%. Using this method allows us to in-
clude more recent transplants with only partial follow-up
available in survival rates. In the case of the center in Ta-
ble 9, this allows us to give credit for improved outcomes
among more recent transplants.
The SRTR also accounts for outcomes among transplant
recipients who become lost to follow-up by examining
additional data sources beyond the transplanting center,
including:
(i) Waiting list additions or retransplants at other centers.
(ii) The Social Security Administration, from death benefit
and employment records.
(iii) CMS billing records and benefit information for kidney
patients.
A comparison with the National Death Index leads us to
believe that by using all of these sources, we are able to
capture more than 99% of the deaths among transplant re-
cipients that occur during the time that these sources—as
well as follow-up forms—are expected to be complete (4).
This considerable certainty allows us to assume, for patient
(not graft) survival analyses, that a patient is alive unless
we know otherwise. Extending the calculations for patients
who have become lost, by adding both death events and
time at risk, a center’s survival rate may improve or be low-
ered. In either case, these calculations are less subject to
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Table 9: Simple Kaplan-Meier calculation
Group A: followed Group B: followed Both Groups
1 year 6 months (A and B)
Transplants 100 100 200
Months 0–6
At risk, start of period 100 100 200
Deaths 14 10 24
Percent survived 86% 90% 88%
Months 7–12
At risk, start of period 86 90 176
Deaths 8 Not yet observed
Percent survived 91% Best guess: 91%
Full 1-year survival 86% × 91% = 78% 90% × 91% = 82% 88% × 91% = 80%
Note: the simple mean of the one-year survival estimates for groups A (78%) and B (82%) equals the
overall survival only because the two groups match each other in size.
Source: SRTR.
Table 10: Excerpts from model description tables, analytic meth-
ods to the center-specific report
Graft survival model description
1 year (and 1 month) after transplant
Organ: heart
Adult (Age 18+)
90.0% graft functioning at 1 year when all covariates = 0.
95.4% graft functioning at 1 month when all covariates = 0.
The indexes of concordance are 63.5%, 65.3%, and 66.2%,
respectively.
Characteristic Standard







Donor age: 0–17 −0.2828 0.1548 0.0677
Donor age: 18–34 −0.2554 0.0990 0.0099
Donor age: 50–64 0.1483 0.1335 0.2666












Source: SRTR Center-Specific Reports, www.ustransplant.org,
July 2005 Release.
biases caused by patients being lost and probably reflect
actual outcomes more accurately. While the effect on na-
tional rates is quite small, it can be quite sizeable—in either
direction—for some centers (5).
As described in Table 8, for graft survival analyses (CSR
Table 10) the KM method is used to estimate survival
percentage after patients are no longer followed by their
center or when lag time prevents complete follow-up. For
Table 11: Range of indexes of concordance, July 2005 posttrans-
plant graft and patient survival models
Models Average Minimum Maximum
Heart 8 60.3% 52.8% 63.5%
Kidney 12 67.4% 60.1% 76.1%
Liver 16 69.1% 61.8% 81.6%
Lung 8 63.2% 61.8% 64.7%
Source: SRTR Center-Specific Reports, www.ustransplant.org,
July 2005 Release.
these graft survival statistics, extra ascertainment of mor-
tality is used only when it indicates a death that occurred
during this reported follow-up time. For patient survival
(CSR Table 11), the KM method is used to estimate survival
only after lag time prevents complete follow-up from any
of the available sources. Portions of the cohorts used for 1-
year survival are recent enough that only a 6-month follow-
up form is reliably expected by the time the CSRs are calcu-
lated. The KM method estimates addresses the follow-up
time after 6 months for these recent transplants.
Both methods are also used in several measures of wait-
ing list outcomes. The KM method is used when patients
transfer to other centers in a time-to-transplant analysis,
assuming that if they had not transferred, their time until
transplant would be similar to other patients at the same
center who had waited as long. Note that in such an anal-
ysis, patients who die are not ‘censored’ in this way, as
we are certain that they would not be transplanted. Extra
ascertainment of mortality is used to identify unreported
deaths before (or soon after) a patient is removed from the
waiting list, but before any transplant event.
Selecting Model Covariates for the
Center-Specific Reports
All of the methods discussed here rely on the concept of
risk adjustment, or asking the question, ‘what result would
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we expect for similar patients, according to the national
experience?’ What variables should be included when we
decide which patients are similar?
Patient characteristics? Almost always. Adjusting for pa-
tient characteristics helps ensure that centers are not
penalized for treating patients who are more likely to
have poorer outcomes. For example, the age of the re-
cipient is closely associated with outcomes, and not
controlling for age might penalize centers that treat
older patients.
Donor characteristics? Much of the time. The current
move toward using more ECD kidneys provides an ex-
cellent example: by not controlling for these characteris-
tics, which are known to result in elevated risk of graft
failure, we would unfairly compare outcomes of ECD
and non-ECD recipients, which might discourage the
use of ECD organs. However, since choosing an appro-
priate donor is important, we may not want to adjust for
all donor characteristics.
Transplant center characteristics? Usually not. Center
volume is a good example of a characteristic that should
not be included in these models even though it may
be associated with better outcomes. In terms of per-
formance, we want to give due credit to larger centers
that perform well rather than adjusting away differences
associated with volume.
The SRTR updates CSRs every 6 months, which allows
ongoing adjustments to be made to the risk-adjustment
models. At each report, the risk adjustment is recalcu-
lated, and each year the SRTR focuses on reviewing the
entire set of risk-adjustment covariates for one or more
organs. Models for kidney survival are being restructured
in 2005 as lung and liver models were in 2004 and heart
models were in 2003. The SRTR plans to continue this
cycle.
Selection of model covariates is based on the entire body of
analytical work performed by the SRTR for the OPTN com-
mittees and other groups. For each report, many separate
models are estimated for each organ. Pediatric and adult
transplants are evaluated with separate models because of
different factors influencing pediatric survival (e.g. immune
responsiveness and compliance with medications). Simi-
larly, separate models are calculated for transplants from
living and deceased donors, for patient and graft survival,
and for different study endpoints (e.g. 1-month vs. 3-year
outcomes). Separating models allows us to use covariates
specific to each transplant type; it also allows their effects
to vary.
Input from the organ-specific OPTN committees is particu-
larly important when considering the clinical plausibility of
each risk-adjustment model. The process for developing
these models involves several steps repeated each time
the models are updated.
Are the data available? The list of covariates that could
be used in these models includes all the data elements
collected by the OPTN during the cohort period. Char-
acteristics that may be clinically significant cannot be
included in the models unless they are collected con-
sistently for all transplant patients in the country, cre-
ating some trade-off between full adjustment and data
submission requirements for transplant centers.
What are the known predictors of survival? From the list
of available covariates, we focus on those shown to be
important in SRTR analyses or the medical literature. We
usually start by including variables that often display p-
values below or nearly below 0.10, even if they may not
be significant at the 0.10 level in this particular model.
In some cases, decisions must be made about which
specific variables to use to incorporate certain factors
into the model when there are several highly associated
variables to choose from. These decisions are based
on significance, interpretability of coefficients and data
quality.
Are there additional factors that we know or suspect
are clinically significant? Based on input from clini-
cal experts from the SRTR and the OPTN organ-specific
committees, additional variables are tested for inclusion
in the model. Some of these are only added to the mod-
els if they reach a certain level of statistical significance;
others may be included regardless of their statistical sig-
nificance because they are widely believed to have an
effect on survival.
Are we modeling each variable correctly? The proper
form must be chosen for each covariate. Some vari-
ables may have a linear relationship with the outcome
(e.g. cold ischemia time may be measured in effect per
hour), while others use categories, allowing nonlinear
relationships between the covariate and outcome. Of-
ten, categorical variables are chosen because of their
versatility. In addition, interactions among variables in
the model are examined.
Communication and documentation of the models
Each risk-adjustment model is published 1 month in ad-
vance of the CSRs. These models are presented as tables
with the features described below; an excerpt from such
a table appears in Table 10.
(i) The beta, or calculated coefficient, shows the ef-
fect of each characteristic on expected risk of death
or graft failure. Some users may be more familiar with
the relative risk of each factor, which can be obtained
by calculating exp(beta).
(ii) The standard error and p-value indicate how much
random variance there was around this estimate, and
our degree of certainty that the given characteristic has
a real effect.
(iii) The index of concordance measures the goodness of
fit for each model. This measure shows the percent-
age of variation in the order of events (deaths or graft
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Table 12: Percentage of centers flagged for adult patient survival
by each review criterion, July 2005 center-specific reports
Kidney Liver Heart Lung All
Number of
programs




21.5% 17.5% 24.5% 24.3% 21.7%
Important:
O−E > 3




7.0% 10.3% 11.2% 9.5% 9.0%
Overlap of flags:
None 77.0% 74.6% 75.5% 71.6% 75.5%
Exactly one 11.7% 11.9% 12.6% 16.2% 12.5%
Exactly two 4.7% 4.0% 4.2% 2.7% 4.2%
All 3 6.6% 9.5% 7.7% 9.5% 7.9%
Source: SRTR.
failures) that is accurately predicted by the model. An
index of concordance of 100% would suggest that the
model perfectly predicts the order of events displayed
in real life; 50% would suggest that the order is random
with regard to predictors. Indexes of concordance are
best for organs with many transplants in each cohort,
such as liver and kidney for adult recipients. Table 11
shows the range of indexes of concordance for the July
2005 reports.
(iv) Models are repeated for a series of three different
cohorts of transplants, allowing a comparison of how
stable the coefficients are across time.
To refer back to the earlier example of adjusting for ECD
kidney donor characteristics, these tables allow us to see
just how these factors are fitted in the model. Examining
the kidney 1-year graft survival model, the fact that a pa-
tient received an ECD organ carries with it an increased risk
of 20%; separately, the models also control for the compo-
nents of the ECD definition—age, hypertension, high cre-
atinine and stroke. By adjusting for all of these character-
istics separately, we adjust for the fact that some ECD
organs carry with them higher risk than others.
Using Center-Specific Outcomes to Select
Centers for Review
The Membership and Professional Standards Committee
(MPSC) of the OPTN works to ensure that member trans-
plant centers remain in compliance with the criteria for
OPTN membership. This role includes identifying centers
that may not perform well, with the intention of helping
them implement corrective action or reconsidering their
membership. Because resources do not allow a close re-
view of practices at all centers, the SRTR worked closely
with the MPSC to develop screening criteria to help iden-
tify and prioritize centers that are more likely to require
attention. These criteria, along with the CSR calculations
on which they are based, also figured prominently in the
proposed Hospital Conditions of Participation for the Medi-
care program recently issued by CMS.
Concepts: actionable, important and significant
To be identified for further review by the MPSC, differ-
ences between observed and expected must meet all of
the following criteria:
(i) Actionable: a clinically significant pattern, suggesting
a higher likelihood that practices contributing to poor
outcomes might be identified, indicated by a high frac-
tion of excess deaths
(a) Standardized Mortality Ratio (SMR) >1.5; observed
deaths divided by expected deaths greater than 1.5
(O/E >1.5)
(b) Interpretation: there were more than 50% more
deaths than expected
(c) CSR Tables 10, 11: line 8
(ii) Important: the magnitude of the problem, in terms of
potential lives saved, should be sufficient to take action
and place the center near the top of the priority list
(a) ‘Excess Deaths’ of at least three; observed deaths
minus expected deaths greater than 3 (O − E > 3)
(b) Interpretation: there were more than three deaths
beyond what would be expected among the recipi-
ent cohort
(c) CSR Tables 10, 11: subtract line 7 from line 6
(iii) Significant: it should be unlikely that the difference
occurred by random chance alone
(a) One-sided p-value less than 0.05 (p < 0.05)
(b) Interpretation: there is less than a 5% chance that
a poor (rather than different in either direction) out-
come occurred by simple random variation
(c) CSR Tables 10, 11: line 10 shows a two-sided p-
value; obtain a one-sided p-value by dividing these
in half, for outcomes where O > E.
Each of these three thresholds is chosen with targeting
facilities for review in mind. It might be possible, after sev-
eral of the centers identified in this fashion have been re-
viewed, to ‘lower’ any of these criteria (using higher p-value
or smaller differences between O and E), identifying ad-
ditional centers. These criteria were designed to identify
centers most in need of review.
In implementing these criteria, all comparisons should be
based on observed and expected events during the time
a patient is actually followed either by the center or, in the
case of patient survival, by extra ascertainment (i.e. they
should not be based on any results imputed by the KM
method). These comparisons should also account for the
difference in outcomes between a patient who dies in the
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Source: SRTR Calculations from July 2005 CSRs. Each point represents a kidney, liver, heart, or lung center in 
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Figure 2: Plot of centers flagged for
adult patient survival by each review
criterion, July 2005 center-specific re-
ports.
first week versus the fifty-first week after transplantation.
Therefore, these criteria are applied to the comparison of
counts of observed and expected deaths as presented in
‘Deaths during follow-up period’, lines 6 and 7, in Table 1—
the comparison described in the third row of Table 5, as
well as to the graft failure equivalent of this outcome.
How many centers are affected, and by which flags?
Figure 2 shows how these three criteria affect actual
centers. Each transplant center is plotted with observed
deaths on the vertical axis and expected deaths on the
horizontal axis (a few of the largest centers, with high ex-
pected deaths, are omitted for scale). The dotted line in-
dicates where observed equals expected; centers that fall
below and to the right of this line have fewer observed
deaths than expected. Three other lines correspond to the
MPSC criteria: (i) parallel to the dotted line, three observed
deaths vertically above, is a line indicating the O−E > 3
threshold; (ii) rising more quickly from the origin with a
slope of 1.5 is a line indicating the O/E > 1.5 threshold;
(iii) the stair-stepped line indicates, for each number of ex-
pected deaths, the number of observed deaths necessary
to achieve a one-sided p-value of <0.05.
To be flagged for review under MPSC (or CMS-proposed)
criteria, a center must have enough observed deaths to
fall above and to the left of all three of these lines. For
most transplant centers, those with expected death counts
between about 2 and 15, the stair-stepped p-value is the
‘binding constraint,’ or the highest of these lines. For some
very small centers, the ‘actionable’ criteria (excess deaths)
is the relevant binding constraint; for the very largest cen-
ters the ‘important’ criteria (SMR > 1.5) is the relevant line.
While many facilities, particularly small ones, have an SMR
above 1.5, very few of these meet either of the other crite-
ria: many of the plotted dots in the lower left-hand corner
are above the SMR line but below both others. For this
reason, the MPSC and the SRTR are developing further
methodology targeted at identifying smaller centers for re-
view. In the meantime, the current methodology is more
likely to prioritize larger centers because of the ‘important’
constraint.
Table 12 shows the number of facilities that fall into each
of these categories according to the July 2005 CSRs. For
each organ shown, at least 20% of centers fall short of at
least one criterion; 7–10% of centers, by organ, are flagged
for review by all the three criteria. Many heart and lung
centers, which tend to be small, fail the O/E criterion, con-
sistent with the data depicted in Figure 2: for centers with
few expected deaths (including small centers), a slight el-
evation in observed deaths may easily meet this criterion
without bringing the center to the binding criterion for small
centers, O−E > 3. The fact that the percent flagged on all
the three criteria is higher than the percent flagged on ex-
actly two confirms correlation among the criteria—centers
with at least two flags are more likely to have all the three
flags qualify.
Comparison to expected versus ranking centers
The comparisons and tests outlined above are intended
to evaluate how well centers perform compared to risk-
adjusted national averages; they are not intended for rank-
ing centers relative to each other. While ordering a list of
centers by observed survival rate is clearly incorrect (as
survival rate may reflect either success or good patient
case mix), even ordering by the SMR is problematic be-
cause of differences in the variance of the SMR estimate
among centers. For example, such an order could imply
that a center with an SMR of 0.8, but not significantly dif-
ferent than expected, performs better than a center with
an SMR of 0.9 that is significantly better than expected;
this is not necessarily true. No p-values or statistical tests
presented measure a real difference between two centers.
Users should be judicious when using or presenting data
that might encourage false comparisons among centers.
Implementing the Screening Concepts
The MPSC continuously reviews program performance, as
authorized by the National Organ Transplant Act (NOTA),
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to oversee the quality of transplant services in the United
States. The committee (made up of transplant profes-
sionals and recipient or donor family representatives)
ensures that OPTN members, including clinical transplant
programs, remain in compliance with OPTN criteria for in-
stitutional membership.
It is the goal of the MPSC review and audit process to
ensure that patients receive quality transplant services
and assist programs with improving their level of care.
Programs that are identified as experiencing lower-than-
expected outcomes first encouraged to implement correc-
tive action, before any recommendations for adverse ac-
tions. However, the MPSC is ultimately responsible for the
welfare of the patients at all centers, including those that
appear to be offering transplant services with outcomes
that are well below those anticipated.
Four times each year, the SRTR provides the MPSC with
an updated report on all transplant programs, without any
indication of transplant center name or location. The report
provides much of the same information shown in Table 1:
the number of transplants performed, the observed and ex-
pected numbers of graft failures and deaths, observed and
expected survival rates and a one-sided p-value to measure
statistical significance. These results, pertaining to 1-year
survival, are shown for two recent and overlapping cohorts
(in 2006, the MPSC will change from 2-year to 2.5-year co-
horts to match the public CSRs). An earlier 5-year cohort
of transplants is also included for historical reference. Each
year, only one pair of transplant cohorts is examined by
the MPSC; updated reports from the SRTR provide more
recent and complete follow-up information, while the co-
hort of transplants examined moves forward only once per
year.
Larger programs (10 or more transplants per cohort) that
meet all the three criteria—actionable, important, and
significant—for two consecutive cohorts, either for graft or
patient survival, enter the MPSC audit process. Requiring
programs to meet all the three criteria for two consecutive
cohorts further ensures that programs are being appropri-
ately identified for evaluation.
Using this methodology, smaller transplant programs
(fewer than 10 transplants per cohort) are rarely flagged
on all the three criteria. Therefore, the MPSC conducts
separate reviews of these programs. The SRTR provides
the MPSC with an annual report listing all small-volume
programs that had at least one death or graft failure during
the evaluation period. The committee then reviews data
on patient outcomes for these centers, including trans-
plant volume summaries, causes of death and graft failure,
comparisons to national survival statistics, performance in
years after the initial review period and survival rates based
on a 5-year cohort. A program may enter the MPSC audit
process if this review reveals concerns about its perfor-
mance. The SRTR and MPSC are currently revising the
methodology for identifying possible underperformers
among small programs.
MPSC audit process
Figure 3 provides an overview of the course of action for
those programs identified for comprehensive MPSC au-
dits. Once a program, either small or large, enters the
MPSC audit process, it is sent an initial survey to validate
the data submitted into UNet, upon which screening crite-
ria were based. This survey requests additional information
on program activity, such as the number of patients evalu-
ated for listing during a designated period, and provides an
opportunity for the program to inform the MPSC of unique
clinical aspects that may have influenced the observed sur-
vival rates. A synopsis of the deaths and graft failures that
occurred within 1 year of transplantation is also requested
for MPSC review. The MPSC considers changes in key per-
sonnel, as well as the causes of graft failure and death, in
determining which programs require further study.
During the audit process, the MPSC may release the pro-
gram from review if the committee is satisfied that the
issues that led to the lower-than-expected outcomes have
been addressed by the program, or if the survival rates in
subsequent years have improved. Alternatively, the MPSC
may continue to monitor the program by following out-
comes in successive recipient cohorts, or it may recom-
mend corrective or adverse actions.
If the MPSC has concerns about the performance of a
transplant program and its ability to improve outcomes on
its own, the committee may offer the program the oppor-
tunity to undergo a site visit from a team usually includ-
ing a transplant surgeon, transplant physician, an adminis-
trator and UNOS/OPTN staff. For 2 days, the team inter-
views key personnel, conducts in-depth reviews of rele-
vant patient charts, and reviews hospital facilities. At the
conclusion of the visit, a preliminary summary of findings
is given to the center, with a formal report submitted to
the MPSC for issuance to the program. The program must
submit an action plan, current data and progress reports
in response to the committee’s recommendations. The
MPSC’s recommendations for corrective action may in-
clude revision and standardization of protocols, such as for
immunosuppression or ECD donors; additional staff such
as social workers, nephrologists, or posttransplant coordi-
nators; implementation of clinical practice guidelines; or al-
location of resources for continuing education for a range of
staff.
The MPSC continues to monitor the program’s progress
in implementing the site visit recommendations as well as
changes in its subsequent outcomes. During monitoring,
the committee may also invite program staff for an infor-
mal discussion of current outcomes and activities; these
discussions do not, in themselves, constitute an adverse
action.
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patient, graft or both:
•One-sided p-value < 0.05
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Figure 3: Overview of MPSC review and corrective action process.
If the MPSC concludes that the program has not taken ap-
propriate steps to improve its outcomes, such as submit-
ting and complying with a corrective action plan, the com-
mittee may recommend to the OPTN Board of Directors
that an adverse action be taken against the program. Rec-
ommended actions could include placing the member on
probation, withdrawing the transplant program from OPTN
membership, or making it a Member (of the OPTN) Not in
Good Standing. Any program recommended for adverse
action is offered due process, including the opportunity to
participate in an interview and present new information, af-
ter which the MPSC may make a recommendation to sus-
tain its previous recommendation, rescind the recommen-
dation, alter the recommendation, or hold the recommen-
dation in abeyance. If the recommendation is sustained,
the program may participate in a formal, in-person, hearing
with the MPSC. Adverse recommendations sustained at
this point may be challenged by appeal to the OPTN Board
of Directors for review.
In an appellate review, programs appear in person and dis-
cuss their challenge to the MPSC recommendation directly
with the OPTN Board. The Board may sustain, alter, or re-
scind the MPSC recommendation. Further appeal may be
directed, in writing, to the Secretary of Health and Human
Services.
Further detail regarding the appeals process may be
found on the OPTN website, at http://www.optn.org/
policiesAndBylaws/bylaws.asp (see Bylaws Appendix A—
Application and Hearing Procedures).
The consequences of being a transplant hospital ‘Member
Not in Good Standing’ may include withdrawal of voting
privileges in OPTN/UNOS affairs, or suspension of the pro-
gram’s personnel from OPTN committees and Board of Di-
rectors. A formal notification of the Member Not in Good
Standing status is made to the OPTN Membership, UNOS,
state health commissioner or other appropriate state repre-
sentative, patients and the general public in the program’s
area, and the Secretary of the Department of Health and
Human Services (HHS).
Since 1999, 261 programs have been reviewed for out-
comes by the MPSC.
Conclusion
Measuring and monitoring performance—be it posttrans-
plant and waiting list outcomes by a transplant center,
or organ donation success by an OPO and its partnering
hospitals—is an important component of ensuring good
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care for people with end-stage organ failure. Many parties
have an interest in examining these outcomes, from pa-
tients and their families to payers such as insurance com-
panies or CMS; from primary caregivers providing patient
counseling to government agencies charged with protect-
ing these patients. It is important for all of these users to
have at their disposal the best statistical methods, com-
puted consistently for all transplant providers, based on
the most reliable and complete data available. Moreover,
it is important that these readers understand the central
concepts important to using these statistics.
In this article, we have used the example of graft and pa-
tient survival to explain these important concepts. It should
be well understood, though, that graft and patient survival
are only a piece of the puzzle constituting good patient care,
and that similar measures are available and pertinent for
waiting list outcomes such as mortality or transplant rates.
All of these measures rely on the concepts described here:
the risk adjustment that allows fair comparison despite dif-
ferences among patients treated, methodology for dealing
with incomplete data and a basic understanding of how to
interpret the magnitude and direction of these outcomes.
We provide a detailed primer on these concepts that will
enable readers to use these statistics wisely, as well as pro-
vide background to some of the statistical methods used
in many other analyses comparing outcomes or perfor-
mance, such as the OPO-specific reports. Finally, we have
offered an example of the effective use of these posttrans-
plant outcome statistics for screening transplant center
performance to identify centers that may need remedial ac-
tion by the OPTN Membership and Professional Standards
Committee.
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